Bayer Reports Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma
Shots:
- The P-III CHRONOS-3 study involves assessing Aliqopa (IV) + rituximab vs PBO + rituximab in 458 patients with relapsed iNHL in extending PFS who have received at least one or more lines of prior rituximab-containing treatment
- Results: @median follow-up of 19.2mos.- mPFS (21.5 vs 13.8 mos.)- ORR (80.8% vs 47.7%)- CR (33.9% and 14.6%)- no new safety signals were identified- overall improvement in the prognosis of iNHL patients
- Aliqopa is a PI3K inhibitor with inhibitory activity against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. The data is presented at AACR 2021 and simultaneously published in The Lancet Oncology
Ref: Businesswire | Image: Business Standard
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com